跳至主要内容
临床试验/NCT02778867
NCT02778867已完成2 期

Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial

Children's Hospital Medical Center, Cincinnati9 个研究点 分布在 1 个国家目标入组 129 人开始时间: 2016年5月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
129
试验地点
9
主要终点
Percent of Participants in Histologic Remission (<15 Eos/Hpf)

研究概览

简要总结

The purpose of this interventional study is to test and compare the effectiveness of two elimination diets-the 1-food elimination diet (1FED, milk only) and the 6-food elimination diet (6FED, milk, egg, wheat, soy, tree nut/peanuts, and fish/shellfish). The study will also test the effectiveness of swallowed glucocorticoid therapy in some of the study participants for whom diet therapy was not effective.

详细描述

This study will consist of two phases, plus a screening period. During the screening period, subject eligibility for the study will be determined. During Phase 1, qualified participants will be randomly assigned to one of two elimination diet therapies--the 1FED or the 6FED. Participants will remain on the assigned dietary therapy for 6 weeks. At the end of 6 weeks of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated to determine disease status. Participants whose EoE is in remission (i.e. <15 eos/hpf) will be done with the study.

Participants whose EoE is still active (i.e. ≥15 eos/hpf) will have the option to continue into Phase 2 of the study. During Phase 2, participants who were on 1FED in Phase 1 will receive 6FED therapy for 6 weeks, and participants who were on 6FED during Phase 1 will receive swallowed glucocorticoid (SGC) therapy for 6 weeks. At the end of 6 weeks of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated to determine disease status.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Have diagnosis of EoE (based on consensus criteria)
  • Have histologically confirmed active disease >15 eosinophils/hpf in either distal or proximal esophagus within 12 weeks of screening visit
  • Symptomatic (have experienced symptoms within the last month prior to enrollment)
  • Proton pump inhibitor (PPI) confirmation
  • Have a negative urine pregnancy test at screening if of childbearing potential

排除标准

  • Have been treated with topical swallowed steroids within the last 2 months or systemic steroids within the last 3 months
  • Have pathological eosinophilia in segments of the GI tract other than the esophagus determined by local review
  • Have been diagnosed with a GI malabsorption disorder (i.e., Inflammatory bowel disease, Crohn's disease) or Celiac disease
  • Are currently on dietary therapy strictly avoiding milk or on a 6FED
  • Have concurrent H pylori gastritis or parasitic infection
  • Have history of anaphylaxis to milk (with current avoidance of milk)
  • Have previously failed strict dietary therapy clearly documented with one of these regimens or topical steroid treatment (i.e. have achieved histological remission of <15 eos/hpf after having been on fluticasone or >1mg budesonide per day).
  • Use of investigational drugs within 4 weeks (one month) prior to enrollment
  • Are concurrently receiving any of the prohibited medications for the study
  • On immunotherapy for pollen (if not on maintenance therapy) or immunoglobulin-E (IgE) -mediated food allergy
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

研究组 & 干预措施

1-Food Elimination Diet (1FED)

Active Comparator

Participants eliminate milk from the diet in Phase 1

干预措施: 1 Food Elimination Diet Therapy (Other)

6-Food Elimination Diet (6FED)

Active Comparator

Participants eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 1

干预措施: 6 Food Elimination Diet Therapy (Other)

1FED Non-Responders (6FED)

Other

Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 2

干预措施: 6 Food Elimination Diet (after 1FED failure) (Other)

6FED Non-responders (SGC)

Other

Participants that fail to respond to 6FED in Phase 1 administer swallowed glucocorticoids (SGC) (Flovent HFA) 880 mcg twice daily in Phase 2

干预措施: Fluticasone Propionate, 880 mcg twice daily (after 6FED failure) (Drug)

结局指标

主要结局

Percent of Participants in Histologic Remission (<15 Eos/Hpf)

时间窗: 6 weeks after starting treatment

Percent of participants in histologic remission in 1FED versus 6FED groups. Remission is defined as esophageal peak eosinophil count \< 15 eosinophils per high powered field (eos/hpf)

次要结局

  • Percent of Participants in Complete and Partial Histologic Remission(6 weeks after starting treatment)
  • Percent of Participants Following SGC in Histologic Remission in Phase 2(6 weeks after starting treatment)
  • Percent of Participants Following 6FED in Histologic Remission in Phase 2(6 weeks after starting treatment)
  • Change From Baseline in Peak Eosinophil Count(6 weeks after starting treatment)
  • Change From Baseline in Total Histology Scoring System(6 weeks after starting treatment)
  • Change From Baseline in Total Endoscopic Reference Score(6 weeks after starting treatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验